Table 1

Relationship between LATS1 or LATS2 mRNA expression levels and clinicopathologic parameters

No. of tumorsmRNA levels (mean ± SE)
LATS1LATS2
Menopausal status
    Premenopausal567.44 ± 1.174.24 ± 0.60
    Postmenopausal615.34 ± 0.613.35 ± 0.43
Tumor size*
    ≤2 cm338.68 ± 1.665.70 ± 0.82
    >2, ≤5cm606.43 ± 0.793.56 ± 0.43
    >5cm232.85 ± 0.461.59 ± 0.67
Histological grade*
    I225.33 ± 1.073.04 ± 0.61
    II676.49 ± 0.964.29 ± 0.58
    III276.88 ± 1.243.10 ± 0.45
Lymph node metastasis
    Negative597.55 ± 0.894.41 ± 0.47
    Positive585.11 ± 0.923.13 ± 0.56
Estrogen receptor
    Positive717.89 ± 0.984.53 ± 0.53
    Negative463.95 ± 0.512.60 ± 0.40
Progesterone receptor
    Positive617.98 ± 0.994.61 ± 0.55
    Negative564.56 ± 0.762.87 ± 0.45
  • * Excludes one noninvasive ductal carcinoma.

  • P < 0.05.

  • P < 0.01.